免疫治疗时代的癌症管理思考
Meditating on Cancer Management at the Time of Immunotherapy.
作者信息
Lopci Egesta
机构信息
Nuclear Medicine, IRCCS-Humanitas Research Center, Via Manzoni 56, 20089 Rozzano, MI, Italy.
出版信息
J Clin Med. 2022 May 27;11(11):3025. doi: 10.3390/jcm11113025.
Abstract
The introduction of checkpoint inhibitors in the last decade has prompted a new era in medical oncology and has opened the door to novel frontiers in cancer treatment [...].
摘要
在过去十年中，检查点抑制剂的引入开创了医学肿瘤学的新纪元，并为癌症治疗的新领域打开了大门[...]。
相似文献
1
Meditating on Cancer Management at the Time of Immunotherapy.
J Clin Med. 2022 May 27;11(11):3025. doi: 10.3390/jcm11113025.
2
Current status of PD-1/PD-L1 blockade immunotherapy in breast cancer.
Jpn J Clin Oncol. 2021 Mar 3;51(3):321-332. doi: 10.1093/jjco/hyaa230.
3
["Immune checkpoint inhibitors in oncology"].
Rev Prat. 2021 Apr;71(4):374-379.
4
Part 1: Imaging findings of common immune checkpoint inhibitor-related adverse effects.
J Med Imaging Radiat Oncol. 2022 Jun;66(4):495-501. doi: 10.1111/1754-9485.13396. Epub 2022 Mar 4.
5
From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
Curr Oncol Rep. 2018 Feb 7;20(1):8. doi: 10.1007/s11912-018-0662-5.
6
Standard therapies: solutions for improving therapeutic effects of immune checkpoint inhibitors on colorectal cancer.
Oncoimmunology. 2020 Jun 3;9(1):1773205. doi: 10.1080/2162402X.2020.1773205.
7
Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy.
Cancer Treat Rev. 2019 Mar;74:49-60. doi: 10.1016/j.ctrv.2018.08.006. Epub 2018 Aug 20.
8
Translating Immuno-oncology Biomarkers to Diagnostic Tests: A Regulatory Perspective.
Methods Mol Biol. 2020;2055:701-716. doi: 10.1007/978-1-4939-9773-2_31.
9
Immunotherapy for Melanoma.
Adv Exp Med Biol. 2021;1342:81-111. doi: 10.1007/978-3-030-79308-1_3.
10
Use of immunotherapy and surgery for stage IV melanoma.
Cancer. 2020 Jun 1;126(11):2614-2624. doi: 10.1002/cncr.32817. Epub 2020 Mar 10.
本文引用的文献
1
Neoadjuvant Chemo-Immunotherapy for Locally Advanced Non-Small-Cell Lung Cancer: A Review of the Literature.
J Clin Med. 2022 May 7;11(9):2629. doi: 10.3390/jcm11092629.
2
Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0.
Eur J Nucl Med Mol Imaging. 2022 Jun;49(7):2323-2341. doi: 10.1007/s00259-022-05780-2. Epub 2022 Apr 4.
3
The Role of Radiomics in the Era of Immune Checkpoint Inhibitors: A New Protagonist in the Jungle of Response Criteria.
J Clin Med. 2022 Mar 21;11(6):1740. doi: 10.3390/jcm11061740.
4
Non-Small-Cell Lung Cancer Patients with Coexistence of High PD-L1 Expression and Fusion-Which Path Should We Follow? Case Reports and Literature Review.
J Clin Med. 2022 Mar 15;11(6):1630. doi: 10.3390/jcm11061630.
5
Checkpoint Inhibitors and the Gut.
J Clin Med. 2022 Feb 4;11(3):824. doi: 10.3390/jcm11030824.
6
Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab.
J Clin Med. 2021 Nov 16;10(22):5325. doi: 10.3390/jcm10225325.
7
Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [F]FDG PET/CT in Metastatic Melanomas and Lung Cancer.
J Clin Med. 2021 Nov 3;10(21):5160. doi: 10.3390/jcm10215160.
8
Predictive Value of Baseline [18F]FDG PET/CT for Response to Systemic Therapy in Patients with Advanced Melanoma.
J Clin Med. 2021 Oct 27;10(21):4994. doi: 10.3390/jcm10214994.
9
Influence of Microbiome and Antibiotics on the Efficacy of Immune Checkpoint Inhibitors.
Cureus. 2021 Aug 2;13(8):e16829. doi: 10.7759/cureus.16829. eCollection 2021 Aug.
10
The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab.
Cancers (Basel). 2021 Jun 22;13(13):3117. doi: 10.3390/cancers13133117.
Zotero 插件